Atlas Antibodies Presents Pan-Cancer Markers and New Product MolBoolean at EACR 2024

Join us at booth 96 at the Annual Congress of the European Association for Cancer Research (EACR) in Rotterdam

We are happy to announce that Atlas Antibodies will be an exhibitor at the Annual Congress of the European Association for Cancer Research (EACR) in Rotterdam, Netherlands (10-13 June 2024)

The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024) is a four-day congress dedicated to basic, preclinical, and translational cancer research across various topics.

It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections, and collaborations.

Pan-Cancer Markers and groundbreaking in situ proximity technology MolBoolean

Join us at booth 96, meet our team onsite and learn more about our unique story, which is closely related to the Human Protein Atlas and our origin.

Besides our strong portfolio of primary antibodies in cancer research, our particular focus will be on the group of primary antibodies (Pan-Cancer Markers for Proteomic Phenotyping) validated on human cancer tissue and cells.

We aim to support proteomic studies, which complement genomics and unveil additional insights into the pathways and processes driving human cancer biology.

The Pan-Cancer Markers presented by Atlas Antibodies represent a significant leap forward in the quest for universally applicable biomarkers across various cancer types.

Learn more about Pan-Cancer Markers

Furthermore, we will present MolBoolean, a groundbreaking in situ proximity technology designed to revolutionize protein analysis.

This pioneering advancement enables the simultaneous detection of free and interacting fractions for two protein targets, promising to accelerate scientific discoveries.

Discover more about MolBoolean